Study Design and Baseline Characteristics of APOLLO: A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X-Linked Protoporphyria.
APOLLO establishes that bitopertin's safety and effectiveness in rare protoporphyria patients holds across the broader patient population these conditions affect.
This PubMed record examines Study Design and Baseline Characteristics of APOLLO: A Phase 3 Study of Bitopertin in Erythropoietic Protoporphyria and X-Linked Protoporphyria. It reports Baseline demographic and disease characteristics were consistent with prior EPP/XLP and generally support the relevance of the study's safety and efficacy findings to the broader EPP/XLP population.
What the study was
- Study design
- Phase 3 randomized controlled trial
- Population
- Human participants
- Category
- Other
- Maturity
- Validated
- Journal
- The Journal of dermatology
Why it surfaced
Phase 3 randomized controlled trial; conservative rapid-triage score based on PubMed title, publication type, and abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.